Explore the words cloud of the INNOHEM project. It provides you a very rough idea of what is the project "INNOHEM" about.
The following table provides information about the project.
Coordinator |
BOULE MEDICAL AB
Organization address contact info |
Coordinator Country | Sweden [SE] |
Project website | http://www.boule.se |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SMEINST-1-2015 |
Funding Scheme | SME-1 |
Starting year | 2015 |
Duration (year-month-day) | from 2015-12-01 to 2016-05-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | BOULE MEDICAL AB | SE (SPANGA) | coordinator | 50˙000.00 |
The INNOHEM project will develop and validate the first Complete Blood cell Count (CBC) haematology analyser including 5-part differential and reticulocytes (5-part analyser) for the decentralized, low-volume testing haematology market. Today, CBC tests are performed using either 3-part or 5-part analysers. The latter are growing in importance worldwide as they are able to provide much more detailed information about the medical condition of the patient. However, 5-part analysers are currently designed entirely for the high-volume testing market with complex, centralized laboratories equipped with large sample automation devices. Recognising market niche and a strong business opportunity, Boule will create a revolutionary point-of-care analyser that will provide reliable 5-part haematology results from a finger-stick blood sample. The new system will disrupt the existing marketplace by redefining the segment for the commercial application of 5-part analysers (from high-volume centralized testing to low-volume near-patient testing). The key need of physicians is the access to an easy-to-deploy analyser for 5-part CBC testing. The analyser should be designed for easy operation in smaller laboratory settings. The users’ needs will be met by creating a user-friendly diagnostic device that allows for low-volume, decentralized and near-patient testing. The Phase 1 project will develop a strategic business plan for the commercialisation of the new product. The Phase 2 project will validate the new diagnostic device. The EU added value will be generated by allowing physicians to make a rapid health assessment of the patient locally and take improved decisions concerning further diagnostic measures or immediate treatment strategy. This will ultimately lead to more personalized and cost-efficient approaches to healthcare on the EU level.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INNOHEM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INNOHEM" are provided by the European Opendata Portal: CORDIS opendata.
Childhood Leukemia: Overcoming distance between South America and Europe Regions
Read MoreEuropean-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development
Read MoreProject on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life
Read More